Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4405-4423

  Gandham, Srujan Kumar ^a   Talekar, Meghna ^a   Singh, Amit ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

3 bromopyruvate; Aerobic glycolysis; Epidermal growth factor receptor targeted liposomes; Hexokinase 2; Ovarian cancer

Indexed keywords

3 BROMOPYRUVATE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEXOKINASE; HEXOKINASE 2; LIPOSOME; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BROMOPYRUVATE;

AEROBIC GLYCOLYSIS; AQUEOUS SOLUTION; ARTICLE; CANCER CELL; CANCER CELL LINE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; MULTICELLULAR SPHEROID; OVARY ADENOCARCINOMA; OVARY TUMOR; STUDENT T TEST; TUMOR SPHEROID; TWO TAILED TEST; AEROBIC METABOLISM; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; METABOLISM; TUMOR CELL CULTURE; TUMOR CELL LINE;

AEROBIOSIS; CELL LINE, TUMOR; FEMALE; GLYCOLYSIS; HEXOKINASE; HUMANS; LIPOSOMES; OVARIAN NEOPLASMS; PYRUVATES; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84937484608     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S82818     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts and Figures 2014. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed May 29, 2015.
2. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010;117(2):152–158.
3. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49 Suppl 2:24S–42S.
4. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633–4646.
5. Fennema E, Rivron N, Rouwkema J, van Blitterswijk C, de Boer J. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 2013;31(2):108–115.
6. Chang TT, Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A. 2009;15(3):559–567.
7. Knuchel R, Hofstadter F, Jenkins WE, Masters JR. Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy. Cancer Res. 1989;49(6):1397–1401.
8. Haycock JW. 3D cell culture: a review of current approaches and techniques. Methods Mol Biol. 2011;695:1–15.
9. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309–324.
10. Mueller-Klieser W, Freyer JP, Sutherland RM. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. Br J Cancer. 1986;53(3):345–353.
11. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr. 2012;44(1):163–170.
12. Pereira da Silva AP, El-Bacha T, Kyaw N, et al. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J. 2009;417(3):717–726.
13. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324(1):269–275.
14. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001;173(1):83–91.
15. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001;276(46):43407–43412.
16. Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213–228.
17. Shoshan MC. 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr. 2012;44(1):7–15.
18. Bangham AD. Liposomes: the Babraham connection. Chem Phys Lipids. 1993;64(1–3):275–285.
19. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. In: Schäfer-Korting M, editor. Drug Delivery. Heidelberg, Germany: Springer; 2010.
20. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008;126(3):187–204.
21. Xu X, Khan MA, Burgess DJ. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm. 2012;423(2):543–553.
22. Magadala P, Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 2008;10(4):565–576.
23. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33(4):369–385.
24. Li Z, Zhao R, Wu X, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19(14):1978–1985.
25. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–899.
26. Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320(5876):661–664.
27. Ward JP, King JR. Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures. Math Biosci. 2003;181(2):177–207.
28. Wenning LA, Murphy RM. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol Bioeng. 1999;62(5):562–575.
29. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud AM, Sgouros G. Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids. J Liposome Res. 2005;15(1–2):15–27.
30. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer. 2004;112(4):713–721.